Biotransplant gibt Gas!!!!!!! - 500 Beiträge pro Seite

[Trinner]

Hallo, hab heute biotransplant inc. (900681) gekauft. kurs 8.80, die quartalszahlen gibts hier:
http://www.brokerat.de
unter börsentipps.

war das ein guter kauf? wo ist das kursziel? meinungen?




<trinner>

[Pozzo]

Glückwunsch!
Verfolge BTRN schon länger,äusserst spekulativ,aber nicht unmöglich.
Ottmar Weber von Cutting Edge sieht ein Henkel-Tasse Chartbild,Ausbruch steht also kurz bevor,der Widerstand bei 8 muss nachhaltig durchbrochen werden,sonst back to 5.
-
Pozzo

[Pozzo]

Die News seit dem 8.6.2001

-
Monday June 11, 6:00 am Eastern Time
Press Release
SOURCE: BioTransplant Incorporated
BioTransplant Completes $19.0 Million Private Placement
CHARLESTOWN, Mass., June 11 /PRNewswire/ -- BioTransplant Incorporated (Nasdaq: BTRN - news) today announced the completion of a $19.0 million private placement of approximately 3,022,457 shares of newly issued common stock, at a purchase price of $6.30 per share, to selected institutional and accredited investors. The Company intends to use the aggregate net proceeds from the private placement of approximately $17.9 million, to advance the Company`s immune modulation therapy programs encompassing the clinical development of its AlloMune(TM) family of product candidates, the expansion of development and commercialization of its Eligix Cell Separation System and to provide it with working capital for other general corporate purposes.

The shares of common stock to be sold in this private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from registration requirements. The Company expects to promptly file a resale registration statement on Form S-3 for purposes of registering the resale of the shares of common stock.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the common stock. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.


BioTransplant Incorporated
Richard Capasso
Vice President, Finance & Treasurer
617-241-5200

Noonan-Russo Communications, Inc.
Prateek Patnaik (Media), ext. 273
Sharon Weinstein (Investor), ext. 334
212-696-4455

SOURCE: BioTransplant Incorporated
-----------------------------------------------------------------


Related Quotes

BTRN
MEDI
7.75
47.20
+0.00
+0.00

delayed 20 mins - disclaimer



Saturday June 23, 2:45 pm Eastern Time
Press Release
SOURCE: MedImmune, Inc.
Initial Clinical Results for MEDI-507 as Psoriasis Treatment Presented at International Psoriasis Symposium
GAITHERSBURG, Md., and CHARLESTOWN, Mass., June 23 /PRNewswire/ -- MedImmune, Inc. (Nasdaq: MEDI - news) and BioTransplant Incorporated (Nasdaq: BTRN - news) announced today that the initial clinical data for MEDI-507 (siplizumab) as a potential treatment for psoriasis was presented at the International Psoriasis Symposium and European Congress on Psoriasis, held in San Francisco, June 19-24, 2001. Results from three clinical trials conducted by MedImmune with siplizumab showed that the drug was generally safe and well tolerated. Patients experienced improvement in psoriasis, as measured by PASI (Psoriasis Area and Severity Index) score via both intravenous and subcutaneous routes of administration. Further, preliminary follow-up data indicates that improvement in patients` psoriasis appears to be durable following completion of treatment.

``We are pleased that siplizumab appears to be safe and well tolerated and is having a clinically meaningful and durable impact on patients` psoriatic disease,`` said James F. Young, Ph.D., MedImmune`s president, research and development. ``We currently have a broad Phase II program underway and expect to provide additional data from our Phase I program later this year at the European Society of Dermatological Research Meeting to be held September 20 - 22, 2001 in Stockholm, Sweden.``

Studies presented Saturday June 23, 2001 at the International Psoriasis Symposium included:


* a Phase I, open-label, single-dose intravenous safety study involving
14 moderate-to-severe psoriasis patients who were given 0.0004 mg/kg,
0.0012 mg/kg, 0.004 mg/kg, or 0.012 mg/kg of siplizumab;
* a Phase I/II, open-label, dose-escalation study involving
26 moderate-to-severe psoriasis patients who received up to 8 weekly
intravenous infusions of siplizumab at 0.0012 mg/kg, 0.004 mg/kg,
0.012 mg/kg or 0.04 mg/kg; and
* a Phase I/II, open-label, dose-escalation study involving
39 moderate-to-severe psoriasis patients who received up to 12 weekly
subcutaneous injections of siplizumab at 0.1 mg, 0.3 mg, 1.0 mg,
3.0 mg, 5.0 mg or 7.0 mg.


In all three studies, siplizumab was found to be generally safe and well tolerated. Side effects were generally considered mild and most commonly included chills and headache in the intravenous studies, and minimal injection site reaction, chills, and headache in the subcutaneous study. Reductions in targeted lymphocyte populations were dose-dependent and less significant when siplizumab was administered subcutaneously.

Improvement in psoriasis, as measured by PASI score, was observed in all dose groups studied and was most notable among patients at the highest dose levels. Overall, more than 70 percent of all patients treated experienced at least 25-percent improvement in PASI score. At the highest dose groups (0.04 mg/kg in the intravenous studies or 5.0 mg and 7.0 mg in the subcutaneous study) more than 55 percent of patients experienced at least a 50-percent improvement, while more than 33 percent showed at least a 75-percent improvement in their disease.

Siplizumab is a humanized monoclonal antibody that binds to the CD2 receptor found on the surface of T-cells and natural killer (NK) cells. By binding to CD2, siplizumab selectively suppresses the function of T-cells and NK cells. T-cells are an essential part of the pathophysiology of psoriasis, and it is believed that modulation of T-cell activities may be therapeutically advantageous in the treatment of psoriasis. Psoriasis is a chronic illness affecting as many as 6 million Americans. Annual outpatient costs for psoriasis management have been estimated to be more than $1 billion.

MedImmune initiated its Phase II development program with siplizumab earlier this year. Currently, the company has two active Phase II trials underway: a randomized, double-blind, placebo-controlled, intravenously dosed Phase II study being conducted at approximately 25 sites in North America involving 124 moderate-to-severe psoriasis patients; and a randomized, double- blind, subcutaneously dosed Phase II trial being conducted at approximately 20 sites in Europe involving approximately 120 moderate-to-severe psoriasis patients.

MedImmune acquired exclusive worldwide rights to siplizumab from BioTransplant in 1995. Siplizumab is the humanized form of BioTransplant`s murine monoclonal antibody, BTI-322. BioTransplant has retained the right to use BTI-322 and/or siplizumab in its proprietary ImmunoCognance(TM) systems, which are designed to re-educate the immune system to accept foreign tissue: the AlloMune(TM) System for human-to-human transplantation, and the XenoMune(TM) System for porcine-to-human transplantation. BTI-322 was initially discovered by Drs. Herve Bazin and Dominique Latinne at the Experimental Immunology Unit of the Catholic University of Louvain in Belgium.

MedImmune, Inc. is a biotechnology company focused on developing and marketing products that address medical needs in areas such as infectious disease, immune regulation and cancer. Headquartered in Gaithersburg, Maryland, MedImmune has manufacturing facilities in Frederick, Maryland and Nijmegen, the Netherlands.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management`s current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in the company`s filings with the U.S. Securities and Exchange Commission. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.

SOURCE: MedImmune, Inc. ---------------------------------------------------------------------------------------------------
weiterhin:BUY
-
Pozzo

[Pozzo]

Laut ----- ist ein grosser Verkäufer vom Markt verschwunden,
hat seine Position abgebaut,erste Erholungsphase steht bevor.
-
Pozzo